EU follows U.S. lead in studying diabetes drugs risks
LONDON, March 26
LONDON, March 26 (Reuters) - The European Medicines Agency said on Tuesday it was investigating the possibility that two widely used classes of diabetes drugs might cause inflammation of the pancreas and pre-cancerous changes.
The decision to study so-called GLP-1 therapies and DPP-4 drugs follows similar action earlier this month by the U.S. Food and Drug Administration.
Drugs affected include Novo Nordisk's Victoza, Merck & Co's Januvia, and Onglyza from Bristol-Myers Squibb and AstraZeneca.
- Search planes scour sea for missing Malaysian jetliner |
- Timeline: Malaysia Airlines flight to Beijing missing in Asia
- Missing Malaysian jet may have disintegrated in mid-air: source |
- Exclusive: Malaysia plane probe narrows on mid-air disintegration - source
- Malaysian plane presumed crashed; questions over false IDs |